New antibody tackles stubborn biofilms in cystic fibrosis lungs
NCT ID NCT06159725
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a single dose of CMTX-101, an antibody designed to break up bacterial biofilms, in 43 adults with cystic fibrosis who have chronic lung infections with Pseudomonas aeruginosa. The goal was to see if adding CMTX-101 to standard inhaled antibiotics is safe and tolerable. The trial focused on safety and how the drug moves through the body, not yet on whether it improves lung function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMTX-101 (a monoclonal antibody that disrupts bacterial biofilms)
- What this could lead to
- If it works, this could point toward a new way to make antibiotics more effective against stubborn lung infections in cystic fibrosis.
- What could go wrong
- This was a small, early-phase safety study (43 people), so it's too soon to know if it actually helps. The treatment is added to existing antibiotics, not a standalone cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Central Florida Pulmonary Group, PA
Orlando, Florida, 32803, United States
-
Cystic Fibrosis Institute
Northfield, Illinois, 60093, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Lenox Hill Hospital
New York, New York, 10075, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
New York Medical College
Hawthorne, New York, 10532, United States
-
PennState Health
Hershey, Pennsylvania, 17003, United States
-
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
St Luke's Sleep Medicine and Research Center
Boise, Idaho, 83702, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
-
University of Alabama, Birmingham
Birmingham, Alabama, 35294, United States
-
University of California, San Francisco
San Franciso, California, 94143, United States
-
University of Kansas
Kansas City, Kansas, 66160, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
Vanderbilt University
Nashville, Tennessee, 37235, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smartphone tool may help cystic fibrosis patients survive the lung transplant waitlist
- Can a smartphone app reveal how CF treatments really work at home?
- Can a peer coach help young people take control of their chronic illness?
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- Could a single antibiotic be enough for cystic fibrosis lung infections?
- Early use of powerful CF drugs may boost growth in young children